Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

Inclusion Criteria: * Age 18-60, no gender limitation * HBsAg is positive for more than 6 months * Hepatitis B e antigen(HBeAg) is negative and anti-HBe is positive * Serum HBV DNA is less than 2000 IU/mL * Alanine aminotransferase(ALT) and/or Aspartate aminotransferase(AST) is normal * No antiviral durg (including nucleos(t)ide analogue and interferon) was used before enrollment * Good compliance and voluntarily signed informed consent Exclusion Criteria: * Allergic to pegylated interferon α-2b * Any indication of liver cirrhosis * Coinfection with hepatitis A virus(HAV), hepatitis C virus(HCV), hepatitis D virus(HDV), hepatitis E virus(HEV) or human immunodeficiency virus(HIV) * Combined with other liver diseases (including drug-related, alcoholic, autoimmune, genetic metabolic liver diseases, etc.) * There are serious lesions in the important organs, such as heart, lung, kidney, brain and fundus * Patients with autoimmune diseases, unstable diabetes or thyroid diseases(hyperthyroidism or hypothyroidism) * Confirmed or suspected liver cancer or other malignant tumors * Patients after or preparing for organ transplantation * Peripheral blood white blood cell count \< 3.5×109/L and/or platelet count \< 80×109/L * Under immunosuppressant treatment * Pregnant or planned pregnancy in a short term or lactation patients * Alcohol abuse (average alcohol intake is more than 40 g/d in males or 20g/d in women) or drug addicts * Present or past history of mental or psychological diseases * Other conditions that the investigators deem inappropriate for the study.